Testing RLY-2608 for growth disorders linked to PIK3CA mutations
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a condition called PROS or another overgrowth condition linked to PIK3CA mutation
- A PIK3CA mutation must be found in tissue from your overgrowth or in your blood
- You should be able to do most daily activities on your own (performance status score of at least 50)
- You must agree to provide a sample of the affected tissue or fluid, or allow a biopsy if it's safe
- You cannot have had any other treatment for your condition within a certain time before starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
This trial tests a new drug called CYH33 for people with conditions caused by a specific gene mutation (PIK3CA) that leads to abnormal tissue growth or blood vessel problems. It aims to see if the drug is safe and can help shrink or control these growths.
This trial tests a drug called alpelisib for children and adults with a rare overgrowth condition called PROS that is caused by a PIK3CA gene change. It aims to see if the drug can safely shrink overgrowth and improve symptoms.
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
This trial tests whether the study drug KP-001 can help reduce symptoms like pain, fatigue, or bleeding caused by certain vascular malformations (abnormal blood vessel growths) that can't be surgically removed or haven't responded to other treatments. It's for people age 2 and older with specific conditions such as common venous malformations, lymphatic malformations, or KTS/CLOVES syndrome.
This Phase 2 study tests alpelisib in children and adults with MCAP, a condition caused by a specific PIK3CA gene mutation. The goal is to see if the treatment is effective and safe, while carefully monitoring blood sugar and organ function.
Hear when a new PIK3CA-Related Overgrowth Spectrum (PROS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.